Is this the best UK stock under £1 right now?

This UK stock currently trades for just 28p. However, Edward Sheldon believes it could rise significantly in the years ahead.

| More on:
UK money in a Jar on a background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There are a lot of UK stocks trading for pennies right now. According to my data provider, there are around 800 stocks on the London Stock Exchange today trading for less than £1.

Now, not all of these companies are worth investing in, of course. There are plenty of low-quality businesses in that group of stocks.

But there are some absolute gems as well. Here’s one that I think is worth considering today.

A 28p growth stock

hVIVO (LSE: HVO) is a small company in the Healthcare sector that specialises in services for clinical trials and lab testing. Headquartered in London, it provides end-to-end early clinical development services to a large, established, and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

Currently, shares in hVIVO trade for just 28p. At that share price, its market-cap is around £189m.

Impressive growth

From an investment perspective, hVIVO’s a lot going for it, in my view.

For starters, it’s growing at an impressive pace. Over the last three years, revenues have climbed from £20.6m to £56m – growth of 172%. This year and next, analysts expect revenue of £61.9m and £67.7m.

It’s worth noting here that the company’s targeting revenue of £100m by 2028. So it clearly expects the growth to continue in the years ahead.

One thing that should help to drive growth is its new state-of-the-art facility in Canary Wharf. This should enable the company to scale up rapidly.

Generating profits

Secondly, the company’s now profitable. This year, analysts expect hVIVO to generate a net profit of £9.1m and earnings per share of 1.41p. Profits are important because they reduce risk for investors. They also make companies much easier to value.

Nice valuation

In terms of the valuation here, it looks attractive to me. Currently, the forward-looking price-to-earnings (P/E) ratio is 19.7, falling to 16.4 using the consensus earnings forecast for 2025.

Given the growth the company’s generating, we appear to have a classic ‘growth-at-a-reasonable-price’ (GARP) stock. Over the years, I’ve found that GARP stocks often outperform the market over time.

Growing dividends

Finally, there are dividends on offer too. The yield here isn’t huge (0.8%) as the company only started paying dividends last year.

But the payout’s growing and I see scope for substantial increases in the years ahead. That’s because the dividend coverage ratio (the ratio of earnings to dividends) is very high at over six.

A lot of potential

Now of course, there are a few risks to consider here. One is volatility in profits, which is quite common among small growth companies in the process of expanding. This could lead to future share price volatility.

Another is complications from clinical trials. This scenario could also lead to share price weakness.

Overall though, I believe this stock has a lot of potential. Of the six brokers covering it, three rate it as a Buy and three have it as a Strong Buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has positions in London Stock Exchange Group Plc. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Growth Shares

Red briefcase with the words Budget HM Treasury embossed in gold
Investing Articles

Could the new UK budget spell growth for these 6 FTSE stocks? I think so!

Mark David Hartley considers six UK stocks that could enjoy growth off the back of new measures announced in the…

Read more »

Investing Articles

At 538p, is the Rolls-Royce share price really that expensive?

The Rolls-Royce share price has continued its incredible post-pandemic rally causing many to ask whether the stock’s overvalued. Our writer…

Read more »

Investing Articles

2 FTSE 100 stocks I’d buy and hold to 2035

A lump sum investment in these FTSE 100 stocks could reap massive returns over the next decade and are worth…

Read more »

Investing Articles

1 FTSE 250 share that can soar like the Rolls-Royce share price

The Rolls-Royce share price has grown almost fivefold since the start of 2023. Muhammad Cheema takes a look at a…

Read more »

Investing Articles

With bad news about the ISA limit, here’s what I’d do

The Budget contained news about the ISA limit for annual contributions being held flat despite inflation. Here's how our writer…

Read more »

Investing Articles

Here are the latest share price forecasts for BAE Systems

The BAE Systems share price has risen around 130% in the last three years. Can it go higher from here?…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Growth Shares

Down 45% in 2024, is the Burberry share price worth backing for 2025?

The Burberry share price has tanked this year, losing almost half its value. Is there potential for a massive rebound…

Read more »

Investing Articles

This ETF is soaring as the gold price booms! Is it time to buy?

Investing in an exchange-traded fund (ETF) like this could be an easy, cheap, and lucrative way to ride the gold…

Read more »